ACT protocols have been used in over 80 disease types in over 700 treatments spanning 4 years with no negative side effects. Benefits have ranged from mild to full restoration in many areas of degenerative disease and injury.
Cord blood stem cells have been used therapeutically since 1988 primarily for the treatment of blood cancers/diseases. In 2001 protocols were developed which allowed for the removal of white blood cells, making this treatment safe (no risk of GVHD) and with no need for HLA matching. In 2002 hallmark studies were released which showed that adult stem cells had the power to reconstitute not only the blood cells, but every other cell in the body. Since this time, ACT protocols have been used in a variety of conditions with significant lasting clinical benefit.
For more information on the areas of application and data, please see the
"
Case Studies" section of this site.
Below follows a list of conditions which have proven responsive to Cord Blood Stem Cell Therapy in house studies (marked *) or have been cited as potential areas of application in international scientific publications.
1) Neurological Disease
| Multiple Sclerosis (MS)* |
Amyotrophic Lateral Sclerosis (ALS)* |
| Parkinson's Disease (PD)* |
Cerebral Palsy (CP)* |
| Autism* |
Guilliame Barre* |
| Transverse Myelitis* |
Basal Ganglia* |
| Supranuclear Palsy* |
Huntington's Disease* |
| Rhett's Syndrome* |
Migraine Headaches* |
| Epilepsy |
Cognitive Dysfunction* |
2) Neurological Injury
| Acute and Chronic Stroke* |
Spinal Cord Injury* |
| Nerve Injury* |
Traumatic Brain Injury* |
3) Blood Cancer
| Acute Lympholastic Leukemia* |
Multiple Myeloma* |
| Non-Hodgkin's Lymphoma* | |
4) Blood Disease
| Wiscott-Aldrich's Syndrome* |
Blood Platelet Disorder* |
| Refractory Anemia* |
Myelodysplasia* |
| Paroxysmal Nocturnal Hemoglobinuria (PNH)* |
Sanfilippo Syndrome |
5) Organ/Tissue Cancers (Immunotherapy)
| Breast Cancer* |
Prostate Cancer* |
| Colon Cancer* |
Pancreatic Cancer* |
| Lung Cancer* |
Malignant Melanoma* |
| Chemo Rescue* |
(All cancers apply) |
6) Viral Conditions
| HIV 1 (no AIDS diagnosis)* |
AIDS (advanced)* |
| Lyme Disease* |
Hepatitis C* |
| Epstein Barr* |
Lyme Disease* |
7) Liver Disease
| Hepatitis B* |
Hepatitis C* |
| Cirrhosis* |
Fibrosis* |
8) Ocular Conditions
| Retinitis Pigmentosa* |
Macular Degeneration* |
| Glaucoma* |
Optic Atrophy |
9) Auto Immune Conditons
| Crohn's Disease* |
Multiple Sclerosis* |
| Rheumatoid Arthritis* |
Lupus |
| Scleroderma* | |
10) Diabetes
| Type 2 (Adult)* |
Type 1 (Child)* |
11) Adrenal Disease
| Addison's Disease* |
Cushings Syndrome |
12) Heart Disease
| Myocardial Infarction |
Dilated Cardiomyopathy* |
| Atherosclerosis |
Congestive Heart Failure |
13) Muscle Disease
| Duchanne's Muscular Dystrophy* | |
14) Renal Disease
15) Skin Disease
Polymyositis*
16) Lung Disease
| Progressive Dyspnea* |
COPD |
| Bronchial Asthma | |
17) Accelerated Surgery or Accident Recovery*
18) Hearing
| Tinnitus |
Injury related hearing loss* |
| Infection related hearing loss* | |
Since the first whole cord blood transplant in 1988, hospital and universities have implemented this treatment thousands of times for blood cancers/diseases.
Studied applications of whole cord blood are listed by the
American Association of Blood Banks (AABB).
Malignant Diseases:
| Acute lymphocytic leukemia |
Acute myelocytic leukemia |
| Juvenile chronic myelogenous leukemia |
Neuroblastoma |
| Chronic myelogenous leukemia |
Nonmalignant Diseases:
| Fanconi anemia |
Aplastic anemia |
| Refractory anemia |
Thalassemia |
| Sickle cell anemia |
Amegakaryocytic thrombocytopenia |
| Kostmann syndrome |
Blackfan-Diamond syndrome |
| Severe combined immunodeficiency |
X-linked lymphoproliferative disorder |
| Wiskott-Aldrich syndrome |
Hurler syndrome |
| Hunter syndrome |
Gunther disease |
| Osteopetrosis |
Globoid cell leukodystrophy |
| Adrenoleukodystrophy | |
The National Marrow Donor Program (NMDP) provides a list of diseases for which unrelated marrow donor transplants (providing adult CD34+ stem cells) have been performed by Transplant Centers in the NMDP Network.
Acute Leukemias
| Acute Lymphoblastic Leukemia (ALL) |
Acute Myelogenous Leukemia (AML) |
| Acute Biphenotypic Leukemia |
Acute Undifferentiated Leukemia |
Chronic Leukemias
| Chronic Myelogenous Leukemia (CML) |
Chronic Lymphocytic Leukemia (CLL) |
| Juvenile Chronic Myelogenous Leukemia (JCML) |
Juvenile Myelomonocytic Leukemia (JMML) |
Myelodysplastic Syndromes
| Myelodysplastic Syndrome |
Refractory Anemia (RA) |
| Refractory Anemia with Ringed Sideroblasts (RARS) |
Refractory Anemia with Excess Blasts (RAEB) |
| Refractory Anemia with Excess Blasts in Transformation (RAEB-T) |
Chronic Myelomonocytic Leukemia (CMML) |
Hematopoitic Cell Disorders
| Aplastic Anemia (Severe) |
Fanconi Anemia |
| Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Pure Red Cell Aplasia |
Myeloproliferative Disorders
| Acute Myelofibrosis |
Agnogenic Myeloid Metaplasia (myelofibrosis) |
| Polycythemia Vera |
Essential Thrombocythemia |
Lymphoproliferative Disorders
| Non-Hodgkin's Lymphoma |
Hodgkin's Disease |
Phagocyte Disorders
| Chediak-Higashi Syndrome |
Chronic Granulomatous Disease |
| Neutrophil Actin Deficiency |
Reticular Dysgenesis |
Inherited Metabolic Disorders
| Mucopolysaccharidoses (MPS) |
Hurler's Syndrome (MPS-IH) |
| Scheie Syndrome (MPS-IS) |
Hunter's Syndrome (MPS-II) |
| Sanfilippo Syndrome (MPS-III) |
Morquio Syndrome (MPS-IV) |
| Maroteaux-Lamy Syndrome (MPS-VI) |
Sly Syndrome, Beta-Glucuronidase Deficiency (MPS-VII) |
| Adrenoleukodystrophy |
Mucolipidosis II (I-cell Disease) |
| Krabbe Disease |
Gaucher's Disease |
| Niemann-Pick Disease |
Wolman Disease |
| Metachromatic Leukodystrophy | |
Histiocytic Disorders
| Familial Erythrophagocytic Lymphohistiocytosis |
Histiocytosis-X |
| Hemophagocytosis | |
Inherited Erythrocyte Abnormalities
| Beta Thalassemia Major |
Sickle Cell Disease |
Inherited Immune System Disorders
| Ataxia-Telangiectasia |
Kostmann Syndrome |
| Leukocyte Adhesion Deficiency |
DiGeorge Syndrome |
| Bare Lymphocyte Syndrome |
Omenn's Syndrome |
| Severe Combined Immunodeficiency (SCID) |
SCID with Adenosine Deaminase Deficiency |
| Absence of T & B Cells SCID |
Absence of T Cells, Normal B Cell SCID |
| Common Variable Immunodeficiency |
Wiskott-Aldrich Syndrome |
| X-Linked Lymphoproliferative Disorder | |
Other Inherited Disorders
| Lesch-Nyhan Syndrome |
Cartilage-Hair Hypoplasia |
| Glanzmann Thrombasthenia |
Osteopetrosis |
Inherited Platelet Abnormalities
Amegakaryocytosis / Congenital Thrombocytopenia
Plasma Cell Disorders
Multiple Myeloma |
Plasma Cell Leukemia |
| Waldenstrom's Macroglobulinemia | |
Other Malignancies
| Breast Cancer |
Ewing Sarcoma |
| Neuroblastoma |
Renal Cell Carcinoma |
Cord Blood Stem Cell therapy(CBSCT) is not a US FDA approved procedure and is in no way to be construed or presented as a cure for any condition, degenerative disease or injury.
Any changes in medication or prescribed treatment program should be made under the supervision of the administering or treating physician.
As with any medical treatment, results from CBSCT should not be undertaken without consulting a qualified physician and Significant Clinical Benefits from CBSCT can not be guaranteed.
Information on this site or in any ACT literature should not be construed to represent a guarantee or claim for a cure or clinical benefit to any disease or injury.
CBSCT does not serve as a substitute for a participant's current medical care and prescribed treatment modalities. Nor is CBSCT intended to serve as a preventive measure, treatment or cure of any condition, degenerative disease or injury.
